TY - JOUR
T1 - Comparison of imaging biomarkers for Alzheimer's disease
T2 - Amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy
AU - Tateno, Amane
AU - Sakayori, Takeshi
AU - Kawashima, Yoshitaka
AU - Higuchi, Makoto
AU - Suhara, Tetsuya
AU - Mizumura, Sunao
AU - Mintun, Mark A.
AU - Skovronsky, Daniel M.
AU - Honjo, Kazuyoshi
AU - Ishihara, Keiichi
AU - Kumita, Shinichiro
AU - Suzuki, Hidenori
AU - Okubo, Yoshiro
N1 - Publisher Copyright:
Copyright © 2014 John Wiley & Sons, Ltd. Copyright © 2014 John Wiley & Sons, Ltd.
PY - 2015/5/1
Y1 - 2015/5/1
N2 - Objective We compared amyloid positron emission tomography (PET) and magnetic resonance imaging (MRI) in subjects clinically diagnosed with Alzheimer's disease (AD), mild cognitive impairment (MCI), and older healthy controls (OHC) in order to test how these imaging biomarkers represent cognitive decline in AD. Methods Fifteen OHC, 19 patients with MCI, and 19 patients with AD were examined by [18F]florbetapir PET to quantify the standard uptake value ratio (SUVR) as the degree of amyloid accumulation, by MRI and the voxel-based specific regional analysis system for AD to calculate z-score as the degree of entorhinal cortex atrophy, and by mini-mental state examination (MMSE) and Alzheimer's Disease Assessment Scale-cognitive component - Japanese version (ADAS-Jcog) for cognitive functions. Results Both cutoff values for measuring AD-like levels of amyloid (1.099 for SUVR) and entorhinal cortex atrophy (1.60 for z-score) were well differentially diagnosed and clinically defined AD from OHC (84.2% for SUVR and 86.7% for z-score). Subgroup analysis based on beta-amyloid positivity revealed that z-score significantly correlated with MMSE (r=-0.626, p<0.01) and ADAS-Jcog (r=0.691, p<0.01) only among subjects with beta-amyloid. Conclusions This is the first study to compare [18F]florbetapir PET and MRI voxel-based analysis of entorhinal cortex atrophy for AD. Both [18F]florbetapir PET and MRI detected changes in AD compared with OHC. Considering that entorhinal cortex atrophy correlated well with cognitive decline only among subjects with beta-amyloid, [18F]florbetapir PET makes it possible to detect AD pathology in the early stage, whereas MRI morphometry for subjects with beta-amyloid provides a good biomarker to assess the severity of AD in the later stage.
AB - Objective We compared amyloid positron emission tomography (PET) and magnetic resonance imaging (MRI) in subjects clinically diagnosed with Alzheimer's disease (AD), mild cognitive impairment (MCI), and older healthy controls (OHC) in order to test how these imaging biomarkers represent cognitive decline in AD. Methods Fifteen OHC, 19 patients with MCI, and 19 patients with AD were examined by [18F]florbetapir PET to quantify the standard uptake value ratio (SUVR) as the degree of amyloid accumulation, by MRI and the voxel-based specific regional analysis system for AD to calculate z-score as the degree of entorhinal cortex atrophy, and by mini-mental state examination (MMSE) and Alzheimer's Disease Assessment Scale-cognitive component - Japanese version (ADAS-Jcog) for cognitive functions. Results Both cutoff values for measuring AD-like levels of amyloid (1.099 for SUVR) and entorhinal cortex atrophy (1.60 for z-score) were well differentially diagnosed and clinically defined AD from OHC (84.2% for SUVR and 86.7% for z-score). Subgroup analysis based on beta-amyloid positivity revealed that z-score significantly correlated with MMSE (r=-0.626, p<0.01) and ADAS-Jcog (r=0.691, p<0.01) only among subjects with beta-amyloid. Conclusions This is the first study to compare [18F]florbetapir PET and MRI voxel-based analysis of entorhinal cortex atrophy for AD. Both [18F]florbetapir PET and MRI detected changes in AD compared with OHC. Considering that entorhinal cortex atrophy correlated well with cognitive decline only among subjects with beta-amyloid, [18F]florbetapir PET makes it possible to detect AD pathology in the early stage, whereas MRI morphometry for subjects with beta-amyloid provides a good biomarker to assess the severity of AD in the later stage.
UR - http://www.scopus.com/inward/record.url?scp=84927038311&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84927038311&partnerID=8YFLogxK
U2 - 10.1002/gps.4173
DO - 10.1002/gps.4173
M3 - Article
C2 - 25043833
AN - SCOPUS:84927038311
SN - 0885-6230
VL - 30
SP - 505
EP - 513
JO - International Journal of Geriatric Psychiatry
JF - International Journal of Geriatric Psychiatry
IS - 5
ER -